CJC-1295 with DAC

CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) developed by ConjuChem Biotechnologies, featuring a Drug Affinity Complex that binds to serum albumin for extended half-life of 6-8 days. Clinical trials demonstrated sustained increases in growth hormone (2-10 fold) for 6+ days and IGF-1 (1.5-3 fold) for 9-11 days after a single injection. The peptide was investigated in Phase 2 trials for HIV-associated lipodystrophy but was discontinued following a participant death, though it showed safety and tolerability in healthy adults at doses of 30-60 μg/kg.

Growth Hormone and IGF-1 Elevation

CJC-1295 with DAC produces sustained, dose-dependent increases in growth hormone and IGF-1 levels in healthy adults, with a single injection causing 2- to 10-fold increases in plasma GH concentrations for 6 days or more and 1.5- to 3-fold increases in IGF-1 concentrations for 9-11 days ^[1]. The peptide maintains GH pulsatility despite continuous stimulation, with preserved pulse frequency and magnitude while increasing baseline GH by 7.5-fold and overall GH secretion by 46% ^[3].

Body Composition and Metabolic Effects

Animal studies demonstrate that CJC-1295 normalizes body weight and composition in GHRH-deficient mice, maintaining normal lean mass and subcutaneous fat distribution with once-daily administration ^[2]. The peptide's activation of the GH/IGF-1 axis results in serum protein profile changes associated with anabolic effects ^[7]. Clinical observations suggest potential for increased lean mass coupled with reductions in visceral fat.

Cardiovascular Health

GHRH analogs, including compounds similar to CJC-1295, have demonstrated significant cardiovascular benefits. Studies show GHRH attenuates cardiac hypertrophy, improves heart function in pressure overload-induced heart failure, and reduces cardiomyocyte apoptosis ^[8]. GHRH agonist treatment improves cardiac performance, reduces infarct size after myocardial infarction, and activates survival kinase pathways including ERK 1/2, PI3K/Akt, and cAMP/PKA signaling ^[8][9].

Anti-Aging and Longevity Effects

GHRH agonists reverse aging-associated changes in cardiac function, exercise activity, immune function, mitochondrial function, and senescence biomarkers in animal models ^[9]. The peptide may enhance slow-wave sleep, the restorative sleep phase where growth hormone is naturally released, with improved sleep quality reported within 1-2 weeks. As growth hormone levels decline with age, CJC-1295's ability to restore GH secretion may mitigate age-related muscle loss, increased body fat, and impaired cognitive function.

Cognitive and Neuroprotective Potential

Preliminary research suggests GHRH analogs may improve cognitive function in adults with mild cognitive impairment by boosting brain chemicals such as GABA and NAAG. Growth hormone receptors are present in brain regions including the hippocampus, which is involved in learning and memory, and IGF-1 has been linked to neurogenesis, synaptic plasticity, and cognitive function. Animal studies indicate GHRH administration may improve cognitive function following traumatic brain injury.

Protein Synthesis and Recovery

CJC-1295 enhances protein synthesis via mTOR and PI3K/Akt pathways, stimulating growth hormone release that plays a vital role in muscle protein synthesis. The peptide demonstrates regenerative properties through satellite cell activation and muscle fiber regeneration. Research indicates enhanced collagen synthesis, connective tissue repair, acceleration of wound healing, and tissue remodeling processes.

Clinical Trial Safety Data

In randomized, placebo-controlled, double-blind trials lasting 28-49 days in healthy adults aged 21-61 years, CJC-1295 was safe and relatively well tolerated at doses of 30 or 60 μg/kg, with no serious adverse reactions reported in initial studies ^[1]. The estimated half-life of 5.8-8.1 days allows for infrequent dosing ^[1][3].

Common Side Effects

Mild injection site reactions (pain, itching, swelling), flushing, water retention, and insomnia were reported as minor, transient side effects ^[1]. At the 100 μg/kg dose, adverse reactions (mainly gastrointestinal) proved more frequent, though no serious adverse events were recorded.

Phase 2 Trial Discontinuation

A Phase 2 multicenter, randomized, placebo-controlled, double-blind study evaluating CJC-1295 in 192 HIV patients with visceral obesity/lipodystrophy was halted after one participant death from myocardial infarction. The attending physician believed the most likely explanation was asymptomatic coronary artery disease with plaque rupture and occlusion, and that the occurrence was unrelated to treatment with CJC-1295. However, this event led to discontinuation of clinical development.

Limited Long-Term Data

Short-term studies have reported CJC-1295 to be safe and relatively well tolerated, but very little data is available on long-term use in healthy individuals. No large-scale studies have evaluated CJC-1295 for longer than 16 weeks. The lack of FDA approval, regulatory restrictions, and limited long-term safety data necessitate careful consideration and medical supervision.

Regulatory Status

CJC-1295 is not FDA-approved for human consumption and is currently classified as an Investigational New Drug in the United States, available exclusively to researchers as a reference material. At the time of clinical development, there were no FDA-approved products containing CJC-1295.

Contraindications and Monitoring

Due to growth hormone's effects on glucose metabolism, monitoring of glucose tolerance and insulin levels is recommended. Individuals with active malignancy, diabetic retinopathy, or cardiovascular disease should exercise extreme caution. The peptide's long half-life means effects persist for days after administration, requiring careful dosing considerations.